The report ?Breast Cancer Drug Discoveries: What the future holds? states that key therapeutic brands achieved sales of US$12.7 billion in 2010, with growth due to higher sales for a number of treatments rather than the launch of new products.
In 2010, nearly 50% of breast cancer sales were due to three branded targeted therapies. With a large unmet clinical need, further agents are necessary to increase survival and delay disease progression. Sales were split between chemotherapies, hormonal therapies and novel molecular targeted therapies, with the majority of these agents used in combination.
According to the 382 page report, by 2017 ten products will command a 77% market share, with the current therapies. Of the current therapies, Roche?s Herceptin and Avastin, along with GSK?s Tykerb/Tyverb, are accounting for over 80% of these sales. Herceptin will remain as the clear market leader.
View the Report
?
Piribo.com is the source for information products concerning the global biotechnology and pharmaceutical industries. Here you can browse and buy thousands of business information studies, market reports and books. Piribo has ongoing relationships with leading market research and publishing companies, so we can offer you a current and comprehensive range of specialised intelligence.
Other Press Releases from Piribo
> World telemedicine market to grow 19% annually to 2014 says new report
> HIV pharmaceutical market leader Gilead reports 13% sales increase
> World cancer generic pharmaceutical market to grow 27% annually to 2014
> Mobile display market to continue 5% annual growth rate says new report
> Molecular imaging market to accelerate to hit US$6 billion by 2015
View all posts by Piribo
This entry was posted in Healthcare, Medical Devices and tagged imaging, molecular. Bookmark the permalink.
national weather service ashley greene weatherchannel rupert grint rupert grint igp igp
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.